Piper Sandler raises Humana stock price target on earnings beat
Piper Sandler raised its price target for Humana (HUM) to $526 from $463, citing strong Q3 2026 earnings and raised 2026 guidance. The firm expects further Medicare Advantage margin expansion and a clear path to $40.45 EPS in 2028. Humana's stock has surged 74% over the past year, and analysts have mixed ratings and targets.
How this was made
The 30-second read
Why it matters
The earnings beat and raised guidance prompted Piper Sandler to lift its price target, indicating a bullish short‑term outlook.
Market read
Humana's strong earnings and upgraded target may drive buying interest in the stock and lift sentiment across the health insurance sector.
What to watch
Potential regulatory changes to Medicare Advantage could affect future performance.
Background
Humana reported Q3 2026 earnings that beat expectations, with revenue of $41.2B and an adjusted EPS loss better than forecast.
Ticker impact
Piper Sandler raised Humana's price target to $526 after the company posted a Q3 earnings beat and raised FY guidance.
likely upward pressure as investors price in the higher target and guidance
Analyst raised target based on beat and guidance lift; market typically reacts positively to such upgrades.
Market effects
Positive for the health insurance sector as Humana's beat may lift peers.
U.S. healthcare stocks could see modest gains.
Limited to U.S. markets; no direct global effect.
Counterpoint
Some investors may view the new target as overly optimistic given valuation concerns.
Key entities
- companyHumana Inc.
U.S. health insurance provider.
- analyst_firmPiper Sandler
Equity research firm that raised the price target.
